Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination - Takeaways - MDSpire

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

  • By

  • Alfred J. Simmons

  • Anna S. Nikonova

  • Chloe D. Jonas

  • Katherine A. Pniewski

  • Deepak Upreti

  • Maria I. Perez

  • Satish Adhikari

  • June 4, 2026

Share

  • 1

    Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with over 80% of cases linked to mutations in the APC gene.

  • 2

    Familial Adenomatous Polyposis (FAP) is a hereditary disorder caused by APC gene mutations, leading to nearly 100% risk of developing CRC.

  • 3

    The study developed a virus-like nanoparticle to deliver a self-amplifying RNA replicon encoding neoantigens from the APC gene.

  • 4

    In vitro tests showed T-cell activation against the neoantigen, indicating potential for a robust immune response in vivo.

  • 5

    The findings support the use of APC-targeted vaccines as a promising strategy for preventing FAP-associated colorectal cancer.

Original Source(s)

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

  • by Alfred J. Simmons, Anna S. Nikonova, Chloe D. Jonas, Katherine A. Pniewski, Deepak Upreti, Maria I. Perez, Satish Adhikari

  • June 4, 2026

Related Content

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

  • by

  • June 2, 2026

  • 2 min
Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib